Search

ANZ-100

Archexin

IPH 2101

IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.

XTL-6865

It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.

AZD-8330

AZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival.

Citatuzumab Bogatox

VB6-845 is a humanized antibody fragment targeting EpCAM fused with the deimmunized form of the cytotoxin Bouganin and is designed for systemic use against metastatic cancer.

Linifanib

Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels

Friulimicin B

Friulimicin B is a naturally occurring antibiotic produced by a micro-organism, *Actinoplanes friuliensis*. … It shows strong cidal activity against a number of Gram-positive pathogens which commonly cause serious infections in hospital patients and which are becoming more routinely acquired in the community.

ABT-560

ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.

3,4-Methylenedioxy-N-isopropylamphetamine

MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF"). … MDI-P has demonstrated potent anti-HIV activity. MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS).